Drugs by Therapeutic Area Market Research

The retinol (vitamin A) market is set to grow at a steady pace with a compounded annual growth rate (CAGR) of 4.8% during the forecast period from 2025 to 2033. Retinol is enlisted in the World Health Organization (WHO) list of essential medicines. It is very useful in maintaining healthy eyesight, skin and immune system. A three pronged approach is used to treat vitamin A deficiency.

Body Worn Temperature Sensors Market Is Projected to Expand At A CAGR Of 21.5% Between 2025 And 2033. Body-worn temperature sensors are emerging as one of the most promising technologies for real-time monitoring of body temperature. The global body worn temperature sensors market is primarily driven by increasing demand for wearable medical devices and is expected to grow incrementally during the forecast period.

Wounds inflicted due to gunshots are very painful and life-threatening if not given immediate medical attention. Hemorrhage or profuse blood loss is the chief cause of mortality seen in military warfare. Rapid and effective management of hemorrhage results in a lifesaving endeavor. Currently there is a rise in the number of criminal violence and accidents occurring which leads to mass killing and traumatic injury which propels the gunshot wounds injury treatment products market growth.

Membrane bioreactors (MBR) are the latest technology used across the globe for waste management and water treatment. Membrane bioreactors comprise a combination of membrane processes such as microfiltration, ultrafiltration, nano-filtration combined with a biological waste-water treatment process.

The global nitric oxide therapy systems market is growing at a CAGR of 5.5% from 2021 to 2029. The nitric oxide therapy systems are majorly utilized in neonatal pulmonary hypertension & acute respiratory distress syndrome. Nitric oxide inhalation through the cyclic GMP induces vasodilation and promotes relief in neonate hypertension and acute respiratory distress syndrome.

Enhancing the viability of preclinical expectations human drugs reactions is critical to reducing expensive failures in clinical trials. The pharmaceutical industry is confronting phenomenal challenges attributable to increasing expenses and the declining efficiency of drug research and development. Late advances in microfabrication, cell biology and microfluidics has empowered the improvement of micro-engineered models of the useful parts of human body known as the organ on chip.

Tardive dyskinesia (TD) is rare neurological disorder due to long term use of antipsychotic medications which act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors such as increasing prevalence of TD, higher number of unmet needs for treatment of TD and expected launch of pipeline drug. Although there are various drugs used in treatment of TD, presently only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents and calcium channel blockers etc. are also used in symptomatic relief from TD.

The dermatology devices market is expected to experience a CAGR of 12% during the forecast period of 2025 to 2033. Dermatology devices are used for diagnosing and treating various skin conditions, including skin cancer, acne, psoriasis, and dermatitis. These devices play a crucial role in enhancing the efficiency and accuracy of dermatological procedures, providing better patient outcomes. The market revenue of dermatology devices is driven by several factors.

Myelodysplastic syndrome (MDS) is type of cancer and it considered as group of blood and bone marrow disorders and involves production of abnormal and immature blood cells. It is anticipated that MDS treatment drugs market will show significant market growth over the forecast period due to rising prevalence of MDS, increase in spending in the healthcare system, growing investments in R&D for MDS treatment and strong presence of ideal pipeline drugs. Expected launch of late stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069 and rigosertib is anticipated to drive significant market growth over the forecast period 2025-2033.

World Health Organization 2018 survey states that globally around 422 million people suffer with diabetes and approximately 2.6 % of the global blindness is due to diabetic retinopathy. The American Academy of Ophthalmology has stated that the incidence rate of diabetic macular edema in a span of 10 years to be 20 % in younger patients and 40 % in older patients. Currently combined therapy of photocoagulation laser therapy and Anti-VEGF drugs are employed to achieve improved vision and avoid blindness.